Cost–effectiveness of novel therapies for overactive bladder. (August 2014)

• Record Type: Journal Article
• Authors: Mayr, Craig A; Shepherd, Jonathan P
• Is Part Of: Expert review of pharmacoeconomics & outcomes research. Volume 14:Number 4(2014)
• Page Start: 527
• Page End: 535
• Publication Date: 2014-08
• Subjects: Pharmacology -- Economic aspects -- Periodicals; 338.47615105
• DOI: 10.1586/14737167.2014.917968
• Languages: English
• ISSNs: 1473-7167

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Overactive bladder is a difficult to treat condition affecting a large proportion of adults resulting in considerable economic impact to society. First-line treatments such as behavioral therapy or antimuscarinic medication are frequently not effective in adequately controlling symptoms or have intolerable side effects. Patients subsequently require second-line therapy including, sacral neuromodulation through either posterior tibial nerve stimulation or sacral nerve stimulation or intra-detrusor injection of Onabotulinumtoxin-A. Mirabegron, a relatively new drug in a separate class, is also employed in the treatment of overactive bladder. The question of which novel therapy to initiate depends on several factors including patient preference, effectiveness and cost. The purpose of this review is to present and discuss the most recent studies pertaining to the cost–effectiveness of novel therapies for overactive bladder.</p> </abstract>